More patients and an improved response rate might once again shift the sentiment on Constellation Pharmaceuticals and its contentious drug for myelofibrosis — this time in a positive direction.
With 63 myelofibrosis patients now treated and evaluable in the company’s mid-stage study, the 24-week spleen response rate to its oral drug, CPI-0610 — when used on top of Jakafi, Incyte’s market-leading drug — stands at 67%. The new data were presented Saturday at the annual meeting of the American Society of Hematology.
About the Author Reprints
